Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.45 -1.4%	$1.41	$1.13 ▼ $2.66	$129.39M	2.61	370,607 shs	173,553 shs
RGNX REGENXBIO	$9.71 -1.5%	$7.82	$5.04 ▼ $15.39	$487.05M	1.11	882,966 shs	645,180 shs
UPB Upstream Bio	$9.16 -1.6%	$8.04	$5.14 ▼ $29.46	$492.75M	N/A	327,321 shs	284,858 shs
ZVRA Zevra Therapeutics	$8.65 +0.9%	$7.59	$4.20 ▼ $9.76	$472.98M	1.87	645,341 shs	375,522 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	0.00%	+4.32%	-2.03%	-31.15%	-38.03%
RGNX REGENXBIO	0.00%	+9.22%	+5.54%	+33.56%	-37.23%
UPB Upstream Bio	0.00%	+6.02%	+2.23%	+14.79%	+915,999,900.00%
ZVRA Zevra Therapeutics	0.00%	-0.12%	+19.48%	+12.63%	+86.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	1.7679 of 5 stars	3.5	4.0	0.0	1.9	0.0	0.0
RGNX REGENXBIO	4.1727 of 5 stars	3.4	2.0	4.6	2.5	3.3	0.6
UPB Upstream Bio	1.8816 of 5 stars	3.5	0.0	0.0	2.5	0.8	0.6
ZVRA Zevra Therapeutics	3.2548 of 5 stars	4.6	2.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	175.86% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	225.70% Upside
UPB Upstream Bio	3.00	Buy	$56.50	516.81% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	157.64% Upside

Current Analyst Ratings Breakdown

Latest CGEN, RGNX, ZVRA, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
3/14/2025	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$22.00 ➝ $24.00
3/14/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/13/2025	ZVRA Zevra Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
3/13/2025	ZVRA Zevra Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/13/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.59M	4.69	N/A	N/A	$0.73 per share	1.99
RGNX REGENXBIO	$156.72M	3.11	N/A	N/A	$7.09 per share	1.37
UPB Upstream Bio	$2.30M	214.61	N/A	N/A	N/A	∞
ZVRA Zevra Therapeutics	$40.59M	11.65	N/A	N/A	$1.71 per share	5.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$18.75M	-$0.16	72.50	N/A	N/A	2.67%	2.62%	1.36%	8/5/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)
UPB Upstream Bio	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/11/2025 (Estimated)
ZVRA Zevra Therapeutics	-$46.05M	-$1.90	N/A	43.25	N/A	-342.63%	-159.54%	-51.50%	8/12/2025 (Estimated)

Latest CGEN, RGNX, ZVRA, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million
3/11/2025	Q4 2024	ZVRA Zevra Therapeutics	-$0.39	-$0.67	-$0.28	-$0.67	$8.93 million	$12.00 million
3/4/2025	Q4 2024	CGEN Compugen	$0.07	-$0.07	-$0.14	-$0.07	$17.47 million	$1.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.14	4.14
RGNX REGENXBIO	N/A	3.05	3.05
UPB Upstream Bio	N/A	N/A	N/A
ZVRA Zevra Therapeutics	0.84	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
RGNX REGENXBIO	88.08%
UPB Upstream Bio	N/A
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
RGNX REGENXBIO	12.79%
UPB Upstream Bio	13.56%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable
UPB Upstream Bio	38	53.79 million	N/A	N/A
ZVRA Zevra Therapeutics	20	54.68 million	52.10 million	Optionable

CGEN, RGNX, ZVRA, and UPB Headlines

Recent News About These Companies

Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 25 at 3:07 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street Zen

May 24 at 11:22 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street Zen

May 24 at 1:21 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LP

May 23 at 6:16 AM | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position

May 21, 2025 | marketbeat.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

May 20, 2025 | marketbeat.com

Research Analysts Offer Predictions for ZVRA Q2 Earnings

May 19, 2025 | americanbankingnews.com

Roth Capital Lifts Earnings Estimates for Zevra Therapeutics

May 18, 2025 | marketbeat.com

Zevra Therapeutics' (ZVRA) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

May 17, 2025 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 14, 2025 | taiwannews.com.tw

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Wednesday

May 9, 2025 | marketbeat.com

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 6, 2025 | globenewswire.com

Barclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 3, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Brokerages

May 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN, RGNX, ZVRA, and UPB Company Descriptions

Compugen NASDAQ:CGEN

$1.45 -0.02 (-1.36%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.42 -0.03 (-2.41%)

As of 05/23/2025 05:47 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

REGENXBIO NASDAQ:RGNX

$9.71 -0.15 (-1.52%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$9.91 +0.20 (+2.05%)

As of 05/23/2025 07:51 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Upstream Bio NASDAQ:UPB

$9.16 -0.15 (-1.61%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$9.15 -0.01 (-0.11%)

As of 05/23/2025 07:52 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Zevra Therapeutics NASDAQ:ZVRA

$8.65 +0.08 (+0.93%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$8.62 -0.03 (-0.36%)

As of 05/23/2025 07:50 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time